|
Market Closed -
Australian S.E.
01:10:10 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 15.73 AUD | +4.31% |
|
-0.76% | +40.45% |
| 09-10 | ASX Biggest Losers | MT |
| 09-02 | ASX Biggest Gainers | MT |
Company Valuation: Telix Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,209 | 2,300 | 3,263 | 8,238 | 3,794 | 5,345 | - | - |
| Change | - | 4.1% | 41.89% | 152.44% | -53.95% | 40.89% | - | - |
| Enterprise Value (EV) 1 | 2,187 | 2,187 | 3,149 | 8,098 | 4,167 | 5,860 | 5,820 | 5,799 |
| Change | - | -0.02% | 44.01% | 157.15% | -48.55% | 40.64% | -0.68% | -0.36% |
| P/E | -27.2x | -21.7x | 626x | 170x | -375x | 221x | 957x | 61.7x |
| PBR | 1,024x | 28.7x | 21.9x | 14.5x | 6.43x | 5.71x | 7.6x | 6.92x |
| PEG | - | -1.2x | -6x | 0x | 3x | -1x | -12.5x | 0x |
| Capitalization / Revenue | 291x | 14.4x | 6.49x | 10.5x | 3.17x | 3.85x | 3.38x | 2.88x |
| EV / Revenue | 288x | 13.7x | 6.27x | 10.3x | 3.48x | 4.22x | 3.68x | 3.12x |
| EV / EBITDA | -31.2x | -32.3x | 53.9x | 81.6x | 74.4x | 65.5x | 69.5x | 33.7x |
| EV / EBIT | -29.1x | -29.9x | 60.9x | 88.7x | 98.7x | 105x | 119x | 43.5x |
| EV / FCF | -35.2x | -29.9x | 223x | 282x | -68.4x | 212x | 784x | 56.3x |
| FCF Yield | -2.84% | -3.35% | 0.45% | 0.35% | -1.46% | 0.47% | 0.13% | 1.78% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.285 | -0.335 | 0.0161 | 0.1446 | -0.0299 | 0.071 | 0.0164 | 0.2551 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7.596 | 160.1 | 502.5 | 783.2 | 1,198 | 1,390 | 1,581 | 1,858 |
| EBITDA 1 | -70.07 | -67.8 | 58.44 | 99.28 | 55.98 | 89.41 | 83.76 | 172.3 |
| EBIT 1 | -75.25 | -73.18 | 51.69 | 91.26 | 42.23 | 55.67 | 48.84 | 133.3 |
| Net income 1 | -80.51 | -104.1 | 5.211 | 49.92 | -10.1 | 27.44 | 6.168 | 86.7 |
| Net Debt 1 | -22.02 | -113 | -114.1 | -139.5 | 372.9 | 515 | 475.2 | 454.4 |
| Reference price 2 | 7.75 | 7.27 | 10.08 | 24.61 | 11.20 | 15.73 | 15.73 | 15.73 |
| Nbr of stocks (in thousands) | 285,073 | 316,343 | 323,727 | 334,724 | 338,721 | 339,784 | - | - |
| Announcement Date | 2/23/22 | 2/27/23 | 2/22/24 | 2/20/25 | 2/19/26 | - | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 221.42x | 4.22x | 65.54x | -.--% | 3.72B | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 45.64x | 24.33x | 20.34x | 0.29% | 37.61B | |
| Weighted average by Cap. | 27.90x | 24.80x | 15.98x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TLX Stock
- Valuation Telix Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
